# Debate Matchup Judgment Report

- template_id: `judge_judge_blend_20260804a__debate_placement_active_20260320f`
- side_swap_group_id: `prop_0650__claude-opus-4-8-adaptive__claude-sonnet-5-high__tpl_placement_active_20260320f`
- topic_id: `prop_0650`
- matchup: **Claude Opus 4.8 (high)** vs **Claude Sonnet 5 (high)**
- overall judged result (normalized): **Tie**
- overall judged result (raw): **Tie**
- mean entertainment: `8.17 / 10`
- mean signed normalized margin for `Claude Opus 4.8 (high)`: `+0.10`
- judgment rows: `6`
- swap_complete: `1`
- rating_eligible: `1`

**Motion:** Widespread adoption of continuous glucose monitors by non-diabetic people will improve public health more than it will fuel anxiety and over-medicalization.

## Source Links

- [Debate A transcript](../../../transcripts/prop_0650__claude-opus-4-8-adaptive__claude-sonnet-5-high__s0__tpl_placement_active_20260320f.md): PRO = **Claude Opus 4.8 (high)**, CON = **Claude Sonnet 5 (high)**
- [Debate B transcript](../../../transcripts/prop_0650__claude-sonnet-5-high__claude-opus-4-8-adaptive__s1__tpl_placement_active_20260320f.md): PRO = **Claude Sonnet 5 (high)**, CON = **Claude Opus 4.8 (high)**
- [Rolling judgment CSV](../../../judgments/judge_results__judge_blend_20260804a.csv)
  Search for `side_swap_group_id=prop_0650__claude-opus-4-8-adaptive__claude-sonnet-5-high__tpl_placement_active_20260320f` or topic `prop_0650`.

## Debate A

- debate_id: `prop_0650__claude-opus-4-8-adaptive__claude-sonnet-5-high__s0__tpl_placement_active_20260320f`
- transcript: [read transcript](../../../transcripts/prop_0650__claude-opus-4-8-adaptive__claude-sonnet-5-high__s0__tpl_placement_active_20260320f.md)
- roles: PRO = **Claude Opus 4.8 (high)**, CON = **Claude Sonnet 5 (high)**
- judged result: Split `2-1` for **Claude Sonnet 5 (high)**.
- entertainment scores: `8`, `8`, `8`
- mean signed raw margin (PRO+): `-0.60`

| Judge | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | Claude Sonnet 5 (high) | -1.8 | -1.53 | 8.0 |
| Kimi K2.6 | Claude Opus 4.8 (high) | +1.5 | +1.70 | 8.0 |
| Qwen 3.7 Max | Claude Sonnet 5 (high) | -1.5 | -1.27 | 8.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview**: Side B won by successfully distinguishing the value of clinical data from the dangers of mass unsupervised data. B's use of the whole-body MRI analogy perfectly illustrated the "denominator" problem in mass screening, neutralizing A's strongest claim about catching silent pred...
  Most decisive rebuttal noted: Side B's Rebuttal 2 was decisive, specifically the answer to A's pressure question about targeted screening. B explained that imperfect data becomes dangerous when stripped of a doctor's clinical context, cleanly separating B's support for targeted screening from A's defense o...
- **Kimi K2.6**: PRO successfully established that the baseline population is not clearly "healthy," undermining CON's worry-well framing by showing silent prediabetes evades risk-factor screening and widespread adoption is the only net that catches those hidden cases. CON landed strong blows...
  Most decisive rebuttal noted: PRO's second rebuttal pressuring the symmetry in CON's position: CON cannot endorse targeted glucose screening while claiming the same glucose data is unusable noise for consumers, since the line between "healthy" and "at-risk" is exactly what is unknown without monitoring.
- **Qwen 3.7 Max**: CON wins by successfully applying core public health screening principles to the motion. The "needle-in-a-haystack" and whole-body MRI analogies effectively neutralized PRO's "cast a wide net" argument by highlighting the denominator problem: the costs of anxiety and over-medi...
  Most decisive rebuttal noted: CON's Rebuttal 2, specifically the A1 response using the whole-body MRI analogy to explain why mass deployment is the wrong instrument for a silent but low-prevalence hidden condition, effectively dismantling PRO's "wide net" justification.

## Debate B

- debate_id: `prop_0650__claude-sonnet-5-high__claude-opus-4-8-adaptive__s1__tpl_placement_active_20260320f`
- transcript: [read transcript](../../../transcripts/prop_0650__claude-sonnet-5-high__claude-opus-4-8-adaptive__s1__tpl_placement_active_20260320f.md)
- roles: PRO = **Claude Sonnet 5 (high)**, CON = **Claude Opus 4.8 (high)**
- judged result: Split `2-1` for **Claude Opus 4.8 (high)**.
- entertainment scores: `9`, `8`, `8`
- mean signed raw margin (PRO+): `-0.57`

| Judge | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | Claude Sonnet 5 (high) | +1.2 | +1.02 | 9.0 |
| Kimi K2.6 | Claude Opus 4.8 (high) | -0.9 | -1.02 | 8.0 |
| Qwen 3.7 Max | Claude Opus 4.8 (high) | -2.0 | -1.70 | 8.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview**: Side A wins by establishing a highly durable asymmetry between the 'soft, correctable' harms of anxiety and the 'hard, compounding' harms of metabolic decline. Side B attempts to sever Side A's solvency by arguing the device doesn't officially diagnose or refer to care, but Si...
  Most decisive rebuttal noted: Side A's second rebuttal exposing the contradiction in Side B's case: a device cannot simultaneously be completely useless because it merely 're-teaches free advice' and powerfully dangerous as an 'engine of an orthorexia epidemic.'
- **Kimi K2.6**: CON successfully identified and exploited the load-bearing weakness in PRO's case: the missing link between CGM data and actual clinical outcomes. While PRO established an undisputed epidemiological problem (widespread undiagnosed prediabetes), CON persuasively argued that the...
  Most decisive rebuttal noted: CON's Rebuttal 2 answer that "behavior change is not the same as health improvement," distinguishing home blood pressure cuffs (validated target, proven outcome) from CGMs for non-diabetics (behavior toward "flatness" with no established benefit), which neutralized PRO's centr...
- **Qwen 3.7 Max**: Side A won by decisively breaking Side B's causal link between consumer CGM adoption and public health improvement. Side A effectively argued that without a validated clinical target for non-diabetics, the device promotes arbitrary "flatness" chasing (risking orthorexia) rathe...
  Most decisive rebuttal noted: Side A's dismantling of Side B's 140 mg/dL threshold, exposing it as a supervised lab diagnostic protocol misapplied to everyday snacking, which perfectly crystallized Side A's core argument that the device generates "noise dressed up as insight" rather than actionable clinica...
